Integra LifeSciences (NASDAQ:IART) Releases Earnings Results

Integra LifeSciences (NASDAQ:IART) issued its earnings results on Thursday. The life sciences company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.04, FiscalAI reports. The company had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a positive return on equity of 14.06% and a negative net margin of 30.15%.The company’s revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.97 earnings per share. Integra LifeSciences updated its Q1 2026 guidance to 0.370-0.450 EPS and its FY 2026 guidance to 2.300-2.400 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Company guides to modest 2026 growth with revenues of $1.66B–$1.70B, adjusted EPS of $2.30–$2.40, expects operating cash flow to exceed $200M, and plans meaningful deleveraging toward a 2.5x–3.5x leverage target by year-end 2026.
• Management says it made material progress on quality and supply reliability—establishing a transformation office and a supply-chain control tower—and is on track to bring the Braintree facility online by end of June to enable a planned Q4 relaunch of SurgiMend.
• Early, accelerated relaunches of PriMatrix and DuraRepair (12 months ahead of plan) had strong customer reception and are expected to contribute to revenue recovery in 2026.
• Tariff uncertainty remains a near-term risk after the Supreme Court ruling and a proposed new Section 122 tariff; Integra paid ~$20M in tariffs in 2025 and continues to model an approximate $0.32 EPS headwind for 2026 while not assuming any recovery of prior payments.
• Tissue Technologies underperformed in Q4 (revenues down 12.8%) driven by ongoing MediHoney remediation and a tough Integra Skin comp, and MediHoney revenue is excluded from 2026 guidance.

Integra LifeSciences Trading Down 2.2%

Shares of NASDAQ:IART opened at $11.33 on Friday. Integra LifeSciences has a twelve month low of $10.60 and a twelve month high of $24.36. The firm has a market cap of $882.49 million, a P/E ratio of -1.75 and a beta of 1.04. The company has a 50 day moving average of $11.99 and a 200-day moving average of $13.20. The company has a current ratio of 3.14, a quick ratio of 1.80 and a debt-to-equity ratio of 1.73.

Analyst Ratings Changes

IART has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Truist Financial restated a “hold” rating and set a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Citigroup decreased their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Finally, Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $15.00.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Adjusted Q4 EPS and revenue beat estimates — Adjusted EPS of $0.83 topped consensus ($0.79) and reported Q4 revenue of $434.9M slightly exceeded expectations, a near‑term sign of underlying demand resilience. Yahoo: Q4 Sales Surprise
• Positive Sentiment: Codman Specialty Surgical segment showed organic growth and product strength — Neurosurgery, Instruments and ENT drove mid‑single digit organic growth and international strength, supporting the company’s core franchise. Press Release
• Neutral Sentiment: Management rolled out a transformation plan with $25–$30M expected savings in 2026 and operational improvements (supply, quality, product relaunches) that could support margin recovery over time. Press Release
• Neutral Sentiment: Guidance is mixed — FY2026 adj. EPS outlook ($2.30–$2.40) is roughly in line with street math but Q1 EPS guidance ($0.37–$0.45) and revenue range sit below consensus, creating near‑term uncertainty. Investing.com: Beats But Guides Below
• Negative Sentiment: Large GAAP impairment and weak GAAP results remain a concern — FY2025 included a $511M goodwill impairment that produced a GAAP net loss (‑$6.74/sh), weighing on reported profitability and investor sentiment. Press Release
• Negative Sentiment: Tissue Technologies decline and cash/leveraging pressure — Tissue revenues fell ~12.8% in Q4; net debt rose to ~$1.6B with a 4.5x leverage ratio, and free cash flow conversion turned negative, elevating balance‑sheet risk until cash generation improves. QuiverQuant: Results & Guidance
• Negative Sentiment: Market reaction/coverage highlights investor caution — Headlines note shares trading down after the print and emphasize the guidance shortfall and impairment history, amplifying short‑term selling pressure. MSN: Stock Trades Down

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP raised its holdings in shares of Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after purchasing an additional 796,300 shares during the period. Kotler Kevin purchased a new stake in shares of Integra LifeSciences during the fourth quarter valued at $5,309,000. Soleus Capital Management L.P. boosted its position in shares of Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after purchasing an additional 315,614 shares during the period. Finally, J. Goldman & Co LP increased its stake in Integra LifeSciences by 30.8% in the 4th quarter. J. Goldman & Co LP now owns 1,243,772 shares of the life sciences company’s stock worth $15,448,000 after purchasing an additional 292,961 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.